You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-Cyclin D1 antibody [SP4]See all Cyclin D1 primary antibodies ...
  • Description
    Rabbit monoclonal [SP4] to Cyclin D1
  • Tested applicationsICC, ICC/IF, WB, IHC-P more details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide (Human) (C terminal).

  • EpitopeC-terminus
  • Positive controlBreast carcinomas

Properties

Applications

Our Abpromise guarantee covers the use of ab16663 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ICC ICC: Use at an assay dependent concentration.
ICC/IF ICC/IF: Use at an assay dependent dilution.
WB WB: 1/200. Predicted molecular weight: 33 kDa.
IHC-P IHC-P: 1/100.

Target

  • FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
  • Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
    Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
    Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
  • Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
  • Post-translational
    modifications
    Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
    Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
  • Cellular localizationNucleus.
  • Target information above from: UniProt accession P24385 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      AI327039 antibodyB cell ccl/lymphoma 1 antibodyB cell CLL/lymphoma 1 antibody
      B cell leukemia 1 antibodyB cell leukemia 1 antibodyB cell lymphoma 1 protein antibodyB-cell lymphoma 1 protein antibodyBCL 1 antibodyBCL-1 antibodyBCL-1 oncogene antibodyBCL1 antibodyBCL1 oncogene antibodyCCND 1 antibodyCCND1 antibodyCCND1 protein antibodyCCND1/FSTL3 fusion gene, included antibodyCCND1/IGHG1 fusion gene antibodyCCND1/IGHG1 fusion gene, included antibodyCCND1/IGLC1 fusion gene, included antibodyCCND1/PTH fusion gene, included antibodyCCND1_HUMAN antibodycD1 antibodyCyl 1 antibodyD11S287E antibodyG1/S specific cyclin D1 antibodyG1/S-specific cyclin-D1 antibodyParathyroid adenomatosis 1 antibodyPRAD1 antibodyPRAD1 oncogene antibodyU21B31 antibody
    see all

Anti-Cyclin D1 antibody [SP4] images

  • Human mantle cell lymphoma stained with ab16663.
  • Lane 1 : Anti-Cyclin D1 antibody [SP4] (ab16663) at 1/200 dilution
    Lane 2 : Anti-Cyclin D1 antibody [SP4] (ab16663) at 1/400 dilution

    Lane 1 : Whole cell lysate prepared from T24 bladder cancer cells
    Lane 2 : Whole cell lysate prepared from T24 bladder cancer cells

    Lysates/proteins at 25 µg per lane.

    Secondary
    Goat anti-rabbit IgG conjugated to HRP at 1/5000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 33 kDa
    Observed band size : 33 kDa


    Exposure time : 10 minutes

    Image kindly supplied by Dr Karin Birkenkamp-Demtroeder through Abreview

    See Abreview

  • ab16663 staining Cyclin D1 in Human urinary tract tissue sections by Immunohistochemistry (IHC-P - formaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 10% BSA for 30 minutes at room temperature; antigen retrieval was by heat mediation in citrate buffer. Samples were incubated with primary antibody (1/100 in PBS) for 1 hour. An undiluted HRP-conjugated Goat anti-rabbit IgG polyclonal was used as the secondary antibody.

    See Abreview

  • Anti-Cyclin D1 antibody [SP4] (ab16663) at 1/25 dilution + MCF7 cell lysate

    Predicted band size : 33 kDa
    Observed band size : 33 kDa
  • Immunohistochemical analysis of mouse testis tissue, staining Cyclin D1 with ab16663.

    Antigen retrieval was performed via Tris-EDTA buffer. Sections were blocked with 3% BSA and incubated with primary antibody (1/50) overnight at 4°C. An AlexaFluor®594-conjugated secondary antibody was used to detect staining.

References for Anti-Cyclin D1 antibody [SP4] (ab16663)

This product has been referenced in:
  • Patel VA  et al. Recognition-dependent Signaling Events in Response to Apoptotic Targets Inhibit Epithelial Cell Viability by Multiple Mechanisms: IMPLICATIONS FOR NON-IMMUNE TISSUE HOMEOSTASIS. J Biol Chem 287:13761-77 (2012). WB . Read more (PubMed: 22396534) »
  • McIver SC  et al. A unique combination of male germ cell miRNAs coordinates gonocyte differentiation. PLoS One 7:e35553 (2012). WB, IHC-P ; Mouse . Read more (PubMed: 22536405) »

See all 14 Publications for this product

Product Wall

Displaying 1 - 10 of 14 results for Abreviews and Q&A

Application Western blot
Sample Human Cell lysate - whole cell (SW480 cells)
Loading amount 25 µg
Specification SW480 cells
Gel Running Conditions Reduced Denaturing (4-12%)
Username

Verified customer

Submitted Jan 24 2013

I am sorry to hear that these antibodies are not providing satisfactory results.

The details provided will enable us to investigate this case and will provide us with vital information for monitoring product quality.

Having reviewed this...

Read More
Application Western blot
Sample Mouse Tissue lysate - whole (fibrotic mouse liver)
Loading amount 20 µg
Specification fibrotic mouse liver
Gel Running Conditions Reduced Denaturing
Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 22°C
Username

Verified customer

Submitted Nov 16 2012

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (organ cultured corneal epithelium)
Specification organ cultured corneal epithelium
Fixative Formaldehyde
Permeabilization Yes - 1% Triton
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 100% · Temperature: 37°C
Username

Verified customer

Submitted Nov 06 2012

Application Immunocytochemistry
Sample Human Cultured Cells (corneal endothelial cells in vitro)
Specification corneal endothelial cells in vitro
Fixative Methanol
Permeabilization No
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 100% · Temperature: 37°C
Username

Verified customer

Submitted Nov 06 2012

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Rat Tissue sections (esophagus)
Specification esophagus
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: 10mM citrate buffer
Permeabilization No
Blocking step DAKO serum free protein blocker as blocking agent for 20 minute(s) · Concentration: 0.25% · Temperature: 28°C
Username

Verified customer

Submitted Apr 16 2012

ab16663 is serum free. I hope this is helpful. Please do not hesitate to contact me with any additional questions.

Application Western blot
Sample Rat Cell lysate - whole cell (Mammary)
Loading amount 30 µg
Specification Mammary
Treatment Estradiol (6 month treatment)
Gel Running Conditions Non-reduced Denaturing (10% Gel was used)
Blocking step Milk as blocking agent for 1 hour(s) and 20 minute(s) · Concentration: 4% · Temperature: 22°C
Username

Verified customer

Submitted Jun 07 2011

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (urinary tract)
Specification urinary tract
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: citrate
Permeabilization No
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 10% · Temperature: rt°C
Username

Verified customer

Submitted Jun 25 2010

Application Western blot
Sample Human Cell lysate - whole cell (T24 bladder cancer)
Loading amount 25 µg
Specification T24 bladder cancer
Gel Running Conditions Reduced Denaturing (4-12% gradient)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Username

Verified customer

Submitted May 06 2010



Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"